Real-world data to the rescue

EVERSANA launches chronic disease real-world data solution to improving patient outcome

Real-world data to the rescue

CHICAGO, Ill.—Calling itself “the pioneer of next-generation commercial services to the global life-sciences industry,” EVERSANA has unveiled its comprehensive data, technology, and services solution to bring real-world data (RWD) to chronic disease research and patient support.

Through the ACTICS technology platform and paired with outsourced service capabilities and patient hub services, EVERSANA’s Chronic Disease Real-World Data solution reportedly enables life-sciences stakeholders to conduct regulatory-grade research studies, generate evidence, and provide insight and proactive support to improve the chronic, comorbid patient experience.

“The use of RWD to generate regulatory-grade evidence in chronic disease has the potential to speed cures to patients, enhance evidence for treatment and give a stronger voice to patients,” said Brigham Hyde, president of the Data & Analytics operation of EVERSANA. “The combination of scaled clinical data with expert curation and data science capability, gives clients the opportunity to make RWD a core part of their clinical and medical strategies for product launch.” 

EVERSANA’s combination of scaled RWD with unstructured content is expected to enable regulatory-grade and scoring used in clinical trials, thus enabling synthetic control comparisons that can speed study times.

RWD “is filling a gap in chronic disease research and evidence generation to maximize the voice of the patient and improve patient outcomes,” Hyde told DDN. “The potential for our RWD solution is it can drive better understanding of clinical outcomes in the real world.”

While placebo-controlled randomized clinical trials remain the gold standard, the evidence of how treatments perform in real-world settings is a critical viewpoint, Hyde said, adding that while trials focus on clear clinical endpoints, sometimes the voice of the patient in the form of patient reported outcomes is a gap in current research. 

“Given the nature of chronic disease patient experiences, especially over many years of treatment and disease burden, patients deserve a significant voice in research,” Hyde added. “The use of RWD also speeds cures by accelerating clinical research through synthetic controls, optimized trial designs, and HEOR research.” 

“From pain and fatigue to socio-behavioral aspects of disease and treatment, chronic disease is marked by often difficult aspects of the patient experience,” Hyde said. “RWD offers an unobstructed view into the longitudinal patient journey, providing a deeper understanding of how a patient’s comorbidities, socioeconomic status, and other clinical and nonclinical factors connect to the quality of clinical outcomes.” 

Also, many patients with chronic disease carry more than one comorbidity, and the potential to understand the impact of that in the treatment setting is crucial to developing effective treatments, Hyde said.

RWD has been gaining traction in various disease areas, including cancer, and Hyde noted that “standards are being set and innovations in technology are underway to standardize this approach and produce reliable evidence to inform patient care. EVERSANA is heavily invested in helping lead this standard development in a transparent fashion that can drive confidence in RWE and determine its most appropriate applications.”

Life-sciences companies have made significant investments in RWD, but most established providers can only deliver a fraction of what is needed to be impactful, Hyde said, pointing out that EVERSANA has insights into 80 million deidentified patients and data science expertise to help partners make RWD a core part of their clinical and medical strategies.

Breaking down traditional healthcare silos for a more innovative approach to drug development can reduce wasted investments and accelerate clinical trials and marketing strategies, he said. 

“On the horizon is the potential to allow scaled RWD to enable personalized medicine and inform unique treatment plans for each patient,” Hyde said. “From the beginnings of drug discovery through post-market safety monitoring, partnering with pioneers who can deliver best-in-class RWD is critical in improving outcomes across the entire health ecosystem. Regulatory agencies in partnership with data companies, manufacturers, and healthcare providers need to continue the process of validation and standard setting to ensure appropriate use of RWD and build the basis for future innovations.”


Reference

EVERSANA https://www.eversana.com 

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue  

• Volume 17 • Issue 5 • May 2021

May 2021

May 2021 issue